[
  {
    "ts": "2025-12-09T08:09:14+00:00",
    "headline": "Is Boston Scientific’s (BSX) Aggressive R&D Push Quietly Redefining Its Long‑Term Growth Story?",
    "summary": "In recent commentary, Boston Scientific highlighted expectations for sustained 8–10% annual revenue growth, margin expansion, and double-digit earnings growth powered by its electrophysiology, structural heart, and minimally invasive portfolios, including strong momentum in its FARAPULSE pulsed-field ablation platform and WATCHMAN left atrial appendage closure device. An interesting aspect of this update is the company's commitment to reinvesting 9–10% of revenue into R&D, underpinning a...",
    "url": "https://finance.yahoo.com/news/boston-scientific-bsx-aggressive-r-080914247.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a091b9c1-3aea-33df-b4cc-596df12b0083",
      "content": {
        "id": "a091b9c1-3aea-33df-b4cc-596df12b0083",
        "contentType": "STORY",
        "title": "Is Boston Scientific’s (BSX) Aggressive R&D Push Quietly Redefining Its Long‑Term Growth Story?",
        "description": "",
        "summary": "In recent commentary, Boston Scientific highlighted expectations for sustained 8–10% annual revenue growth, margin expansion, and double-digit earnings growth powered by its electrophysiology, structural heart, and minimally invasive portfolios, including strong momentum in its FARAPULSE pulsed-field ablation platform and WATCHMAN left atrial appendage closure device. An interesting aspect of this update is the company's commitment to reinvesting 9–10% of revenue into R&D, underpinning a...",
        "pubDate": "2025-12-09T08:09:14Z",
        "displayTime": "2025-12-09T08:09:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFax.1EIpS7VVYvaDN0jRw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OB69YGFZw788CGHTsahrkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-bsx-aggressive-r-080914247.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-bsx-aggressive-r-080914247.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]